ATP结合转运蛋白C4与肿瘤及化疗药物的研究进展

doi:10.3760/cma.j.issn.1673422X.2015.05.013

摘要/Abstract

摘要： ATP结合转运蛋白C4（ABCC4，MRP4）对于转运生理性、内源性或者外源性物质起重要作用。ABCC4基因在多种实体肿瘤和血液系统肿瘤中表达增高，并影响转移复发等过程。并且ABCC4可降低多种化疗药物的细胞内浓度，下调细胞对化疗药物的敏感性，导致患者预后不良。

关键词: 肿瘤/药物疗法/抗药性, 肿瘤/ATP结合转运蛋白C4

Abstract: ATP binding cassette C4 (ABCC4, MRP4) plays an important role in transshipment physiologic, endogenous or exogenous substances. The over expression of ABCC4 gene has been found in many kinds of solid tumors and hematological malignancies. The target gene also influences metastasis and recurrence process. ABCC4 can reduce the intracellular concentration and the sensitivity of various chemotherapy drugs, which is bad for prognosis.

Key words: Neoplasms/Drug therapy/Drug resistance, neoplasm/ATPbinding cassette transporter C4

阎瑾, 赵晓婷, 江妹, 岳文涛. ATP结合转运蛋白C4与肿瘤及化疗药物的研究进展[J]. 国际肿瘤学杂志, 2015, 42(5): 367-370.

YAN Jin, ZHAO Xiao-Ting, JIANG Mei, YUE Wen-Tao. Development of ABCC4 on various tumors and chemotherapy drugs[J]. Journal of International Oncology, 2015, 42(5): 367-370.

参考文献

［1］ Adema AD, Floor K, Smid K, et al. Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine［J］. Springerplus， 2014, 3:732. ［2］ Russel FG, Koenderink JB, Masereeuw R. Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules［J］. Trends Pharmacol Sci， 2008, 29(4):200207. ［3］ Carozzo A, Diez F, Gomez N, et al. Dual Role of cAMP in the Transcriptional Regulation of Multidrug ResistanceAssociated Protein 4 (MRP4) in Pancreatic Adenocarcinoma Cell Lines［J］. PLoS One， 2015, 10(3):e120651. ［4］ Markova S M, Kroetz DL. ABCC4 is regulated by microRNA124a and microRNA506［J］. Biochem Pharmacol， 2014, 87(3):515522. ［5］ Liu YH, Di YM, Zhou Z W, et al. Multidrug resistanceassociated proteins and implications in drug development［J］. Clin Exp Pharmacol Physiol， 2010, 37(1):115120. ［6］ Lin F, Marchetti S, Pluim D, et al. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues［J］. Clin Cancer Res， 2013, 19(8):20842095. ［7］ van de Ven R, de Groot J, Reurs AW, et al. Unimpaired immune functions in the absence of Mrp4 (Abcc4)［J］. Immunol Lett， 2009, 124(2):8187. ［8］ Qian Z, Zhu G, Tang L, et al. Whole genome gene copy number profiling of gastric cancer identifies PAK1 and KRAS gene amplification as therapy targets［J］. Genes Chromosomes Cancer， 2014, 53(11):883894. ［9］ Chen L, Gu J, Xu L, et al. RNAimediated silencing of ATPbinding cassette C4 protein inhibits cell growth in MGC803 gastric cancer cell lines［J］. Cell Mol Biol (Noisylegrand)， 2014, 60(1):15. ［10］ Wu Q, Li ZS, Li D W, et al. Relationship between the expression of hypoxiainducible factor1alpha and chemotherapy response in gastric carcinoma［J］. Zhonghua Wei Chang Wai Ke Za Zhi， 2009, 12(5):498501. ［11］ Hagmann W, Jesnowski R, Faissner R, et al. ATPbinding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5fluorouracilresistant cells［J］. Pancreatology， 2009, 9(12):136144. ［12］ Zhang Z, Wang J, Shen B, et al. The ABCC4 gene is a promising target for pancreatic cancer therapy［J］. Gene， 2012, 491(2):194199. ［13］ Zhao X, Guo Y, Yue W, et al. ABCC4 is required for cell proliferation and tumorigenesis in nonsmall cell lung cancer［J］. Onco Targets Ther， 2014, 7:343351. ［14］ Mayba O, Gnad F, Peyton M, et al. Integrative analysis of two cell lines derived from a nonsmalllung cancer patient—a panomics approach［J］. Pac Symp Biocomput， 2014: 7586. ［15］ Moyer AM, Sun Z, Batzler AJ, et al. Glutathione pathway genetic polymorphisms and lung cancer survival after platinumbased chemotherapy［J］. Cancer Epidemiol Biomarkers Prev， 2010, 19(3):811821. ［16］ Wang JL, Chai YH, Ji ZH, et al. Preliminary study of gene expression profile associated with risk classification of childhood patients with acute lymphoblastic leukemia［J］. Zhonghua Xue Ye Xue Za Zhi， 2011, 32(1):2933. ［17］ Copsel S, Bruzzone A, May M, et al. Multidrug resistance protein 4/ ATP binding cassette transporter 4: a new potential therapeutic target for acute myeloid leukemia［J］. Oncotarget， 2014, 5(19):93089321. ［18］ Montani M, Hermanns T, Muntener M, et al. Multidrug resistance protein 4 (MRP4) expression in prostate cancer is associated with androgen signaling and decreases with tumor progression［J］. Virchows Arch， 2013, 462(4):437443. ［19］ Bagnoli M, Beretta GL, Gatti L, et al. Clinicopathological impact of ABCC1/MRP1 and ABCC4/MRP4 in epithelial ovarian carcinoma［J］. Biomed Res Int， 2013, 2013:143202. ［20］ Zhang YH, Wu Q, Xiao XY, et al. Silencing MRP4 by small interfering RNA reverses acquired DDP resistance of gastric cancer cell［J］. Cancer Lett， 2010, 291(1):7682. ［21］ LopezLopez E, Ballesteros J, Pinan MA, et al. Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia［J］. Pharmacogenet Genomics， 2013, 23(2):5361. ［22］ Li F, Fridley BL, Matimba A, et al. Ecto5'nucleotidase and thiopurine cellular circulation: association with cytotoxicity［J］. Drug Metab Dispos， 2010, 38(12):23292338. ［23］ Bamba S, Tsujikawa T, Sasaki M, et al. Immunomodulators and immunosuppressants for Japanese patients with ulcerative colitis［J］. ISRN Gastroenterol， 2011, 2011:194324. ［24］ Tanaka Y, Manabe A, Fukushima H, et al. Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia［J］. Pharmacogenomics J， 2014， In press. ［25］ Wakamatsu T, Nakahashi Y, Hachimine D, et al. The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistanceassociated proteins［J］. Int J Oncol， 2007, 31(6):14651472. ［26］ Zhang G, Wang Z, Qian F, et al. Silencing of the ABCC4 gene by RNA interference reverses multidrug resistance in human gastric cancer［J］. Oncol Rep， 2015, 33(3):11471154. ［27］ Huynh T, Norris MD, Haber M， et al. ABCC4/MRP4: a MYCNregulated transporter and potential therapeutic target in neuroblastoma［J］. Front Oncol， 2012, 2:178.